These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34206708)

  • 41. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic kidney disease: effects on the cardiovascular system.
    Schiffrin EL; Lipman ML; Mann JF
    Circulation; 2007 Jul; 116(1):85-97. PubMed ID: 17606856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease.
    Ashby EL; Kehoe PG
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1229-42. PubMed ID: 23800077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice.
    Auron M; Harte B; Kumar A; Michota F
    Postgrad Med J; 2011 Jul; 87(1029):472-81. PubMed ID: 21441164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is there a future for direct renin inhibitors?
    Chaudhary K; Nistala R; Whaley-Connell A
    Expert Opin Investig Drugs; 2010 May; 19(5):653-61. PubMed ID: 20380486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. It is time to reconsider the cardiovascular protection afforded by RAAS blockade -- overview of RAAS systems.
    Tsukamoto O; Kitakaze M
    Cardiovasc Drugs Ther; 2013 Apr; 27(2):133-8. PubMed ID: 22147138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renin angiotensin system and ASCVD.
    Farmer JA
    Curr Opin Cardiol; 2000 May; 15(3):141-50. PubMed ID: 10952419
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease.
    Re RN
    Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):42-7. PubMed ID: 16265259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V
    J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The renin-angiotensin-aldosterone system: a specific target for hypertension management.
    Weir MR; Dzau VJ
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):205S-213S. PubMed ID: 10619573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
    Slomka T; Lennon ES; Akbar H; Gosmanova EO; Bhattacharya SK; Oliphant CS; Khouzam RN
    Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New approaches to blockade of the renin-angiotensin-aldosterone system: overview of regulation of the renin-angiotensin-aldosterone system.
    Nishiyama A; Kim-Mitsuyama S
    J Pharmacol Sci; 2010; 113(4):289-91. PubMed ID: 20675960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insights into the emerging cardiometabolic prevention and management of diabetes mellitus.
    Lastra-Gonzalez G; Manrique CM; Govindarajan G; Whaley-Connell A; Sowers JR
    Expert Opin Pharmacother; 2005 Oct; 6(13):2209-21. PubMed ID: 16218882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [RAAS and insulin resistance].
    Motoshima H; Araki E
    Nihon Rinsho; 2012 Sep; 70(9):1542-9. PubMed ID: 23012801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.